share_log

LifeTech Scientific's (HKG:1302) Five-year Earnings Growth Trails the Respectable Shareholder Returns

LifeTech Scientific's (HKG:1302) Five-year Earnings Growth Trails the Respectable Shareholder Returns

LifeTech Scientific(HKG: 1302)的五年收益增長落後於可觀的股東回報
Simply Wall St ·  2023/10/12 19:04

While LifeTech Scientific Corporation (HKG:1302) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 18% in the last quarter. But that doesn't change the fact that the returns over the last five years have been pleasing. After all, the share price is up a market-beating 45% in that time.

而當生命科技科技公司(HKG:1302)股東可能普遍滿意,該股最近表現不是特別好,股價在上個季度下跌了18%。但這並不能改變過去五年回報一直令人滿意的事實。畢竟,在這段時間裡,該公司股價上漲了45%,漲幅超過了市場。

The past week has proven to be lucrative for LifeTech Scientific investors, so let's see if fundamentals drove the company's five-year performance.

過去一週對LifeTech Science的投資者來說被證明是有利可圖的,所以讓我們看看基本面因素是否推動了該公司五年的業績。

See our latest analysis for LifeTech Scientific

查看我們對LifeTech Science的最新分析

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用巴菲特的話說,“船隻將在世界各地航行,但平坦的地球協會將蓬勃發展。市場上的價格和價值之間將繼續存在巨大的差異……”考察市場情緒如何隨時間變化的一種方法是觀察一家公司的股價和每股收益(EPS)之間的相互作用。

Over half a decade, LifeTech Scientific managed to grow its earnings per share at 16% a year. The EPS growth is more impressive than the yearly share price gain of 8% over the same period. So one could conclude that the broader market has become more cautious towards the stock.

在過去的五年裡,LifeTech Science設法以每年16%的速度增長每股收益。每股收益的增長比同期8%的年股價漲幅更令人印象深刻。因此,人們可以得出結論,更廣泛的市場對該股已變得更加謹慎。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

您可以在下面看到EPS是如何隨著時間的推移而變化的(通過單擊圖像來了解確切的值)。

earnings-per-share-growth
SEHK:1302 Earnings Per Share Growth October 12th 2023
聯交所:2023年10月12日每股收益增長1302

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

在買賣股票之前,我們總是建議仔細研究一下歷史增長趨勢,可以在這裡找到。

A Different Perspective

不同的視角

Investors in LifeTech Scientific had a tough year, with a total loss of 7.2%, against a market gain of about 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 8%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Is LifeTech Scientific cheap compared to other companies? These 3 valuation measures might help you decide.

LifeTech Science的投資者經歷了艱難的一年,總虧損7.2%,而市場收益約為12%。然而,請記住,即使是最好的股票,在12個月的時間裡,有時也會表現遜於市場。較長期的投資者不會如此沮喪,因為他們在五年內每年會獲得8%的收益。如果基本面數據繼續顯示長期可持續增長,當前的拋售可能是一個值得考慮的機會。LifeTech Science與其他公司相比便宜嗎?這3個估值指標可能會幫助你做出決定。

Of course LifeTech Scientific may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然了LifeTech Science可能不是最值得買入的股票那就是。所以你可能想看看這個免費成長型股票的集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

請注意,本文引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論